Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

The relationship between dry eye disease and anticholinergic burden

Eye volume 37, pages 2921–2925 (2023)Cite this article

Subjects

Abstract

Purpose

Anticholinergic drugs are widely prescribed for many medical conditions. However, data on the association of anticholinergic burden with dry eye disease (DED) are limited. In this study, we aimed to examine the relationship between anticholinergic burden and DED.

Methods

In this retrospective cohort study, we evaluated a total of 120 participants who underwent ophthalmological examination between February 2021 and February 2022. The drugs used by the patients in the last 2 months were recorded from the institute’s electronic data system. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden (ACB) scale.

Results

The mean age of those patients was 59.0 ± 11.6 years and more than half (n = 33, 64.7%) were women. Patients with DED had significantly higher Charlson comorbidity index scores (p = 0.01), lower Schirmer test values (p = 0.01), higher Ocular Surface Disease Index (OSDI) scores (p = 0.01), and higher anticholinergic burden (p = 0.01). There was a statistically significant positive correlation between ACB and OSDI scores (r = 0.22, p = 0.02) and a negative correlation between ACB scores and Schirmer test values (r = −0.46, p = 0.01). After adjusting for potential confounding factors (age, gender, and comorbidities), each 1-point increase in anticholinergic burden was found to result in a 2.97-fold increase in the risk of DED (OR: 2.97, 95% confidence interval: 1.22–7.24, p = 0.02).

Conclusion

Anticholinergic burden appears to be associated with DED. Therefore, greater caution in prescribing anticholinergic drugs for adult patients may be important in reducing the rates of many adverse outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

Data availability

The database is available from the corresponding author upon reasonable request.

References

  1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.

    Article  PubMed  Google Scholar 

  2. Farrand KF, Fridman M, Stillman I, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–8.

    Article  PubMed  Google Scholar 

  3. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–65.

    Article  PubMed  Google Scholar 

  4. Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799–806.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Latkany R. Dry eyes: Etiology and management. Curr Opin Ophthalmol. 2008;19:287–91.

    Article  PubMed  Google Scholar 

  6. Asiedu K. Role of ocular surface neurobiology in neuronal-mediated inflammation in dry eye disease. Neuropeptides. 2022;95:102266.

    Article  CAS  PubMed  Google Scholar 

  7. Gilbard JP. The diagnosis and management of dry eyes. Otolaryngol Clin North Am. 2005;38:871–85.

    Article  PubMed  Google Scholar 

  8. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.

    Article  CAS  PubMed  Google Scholar 

  9. Wolpert LE, Snieder H, Jansonius NM, Utheim TP, Hammond CJ, Vehof J. Medication use and dry eye symptoms: A large, hypothesis-free, population-based study in the Netherlands. Ocul Surf. 2021;22:1–12.

    Article  PubMed  Google Scholar 

  10. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007;67:75–93.

    Article  CAS  PubMed  Google Scholar 

  11. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opin Drug Saf. 2011;10:751–65.

    Article  PubMed  Google Scholar 

  12. Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404–37.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56:1333–41.

    Article  PubMed  Google Scholar 

  14. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr. 2015;15:1–14.

    Article  Google Scholar 

  16. Cebron Lipovec N, Jazbar J, Kos M. Anticholinergic burden in children, adults and older adults in Slovenia: A nationwide database study. Sci Rep. 2020;10:9337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale. Drugs Aging. 2013;30:103–12.

    Article  CAS  PubMed  Google Scholar 

  18. Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr. 2002;14:307–10.

    Article  PubMed  Google Scholar 

  19. Vetrano DL, La Carpia D, Grande G, Casucci P, Bacelli T, Bernabei R, et al. Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. J Am Med Dir Assoc. 2016;17:1056–9.

    Article  PubMed  Google Scholar 

  20. Graves-Morris K, Stewart C, Soiza RL, Taylor-Rowan M, Quinn TJ, Loke YK, et al. The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: A systematic review and meta-analysis. Front Pharmacol. 2020;11:570.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lavrador M, Cabral AC, Figueiredo IV, Veríssimo MT, Castel-Branco MM, Fernandez-Llimos F. Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients. Int J Clin Pharm. 2021;43:128–36.

    Article  CAS  PubMed  Google Scholar 

  22. Lozano-Ortega G, Johnston KM, Cheung A, Wagg A, Campbell NL, Dmochowski RR, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87:103885.

    Article  CAS  PubMed  Google Scholar 

  23. Wong J, Lan W, Ong LM, Tong L. Non-hormonal systemic medications and dry eye. Ocul Surf. 2011;9:212–26.

    Article  PubMed  Google Scholar 

  24. Li N, Deng XG, He MF. Comparison of the Schirmer I test with and without topical anesthesia for diagnosing dry eye. Int J Ophthalmol. 2012;5:478–81.

    PubMed  PubMed Central  Google Scholar 

  25. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22:640–50.

    Article  PubMed  Google Scholar 

  26. Dogac A, Yuksel M, Avcl A, Ceyhan B, Hülür Ü, Eryllmaz Z, et al. Electronic health record interoperability as realized in the Turkish health information system. Methods Inf Med. 2011;50:140–9.

    Article  CAS  PubMed  Google Scholar 

  27. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: A review and practical application. Aging Health. 2008;4:311–20.

  28. Campbell N, Maidment I, Fox C, Khan B, Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc. 2013;61:S142–3.

    Google Scholar 

  29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Clin Epidemiol. 1987;40:373–83.

    CAS  Google Scholar 

  30. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.

    Article  CAS  PubMed  Google Scholar 

  31. Vehof J, Snieder H, Jansonius N, Hammond CJ. Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. Ocul Surf. 2021;19:83–93.

    Article  PubMed  Google Scholar 

  32. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511–38.

    Article  PubMed  Google Scholar 

  33. Wouters H, van der Meer H, Taxis K. Quantification of anticholinergic and sedative drug load with the Drug Burden Index: a review of outcomes and methodological quality of studies. Eur J Clin Pharm. 2017;73:257–66.

    Article  CAS  Google Scholar 

  34. Szabo SM, Gooch K, Schermer C, Walker D, Lozano-Ortega G, Rogula B, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9:e026391.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kawashima M, Yamada M, Shigeyasu C, Suwaki K, Uchino M, Hiratsuka Y, et al. Association of systemic comorbidities with dry eye disease. J Clin Med. 2020;9:2040.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IÖ. Comorbidities and prescribed medications in patients with or without dry eye disease: a population-based study. Am J Ophthalmol. 2019;198:181–92.

    Article  PubMed  Google Scholar 

  37. Roh HC, Lee JK, Kim M, Oh J-H, Chang M-W, Chuck RS, et al. Systemic comorbidities of dry eye syndrome: the Korean National Health and Nutrition Examination Survey V, 2010 to 2012. Cornea. 2016;35:187–92.

    Article  PubMed  Google Scholar 

  38. Heidari M, Noorizadeh F, Wu K, Inomata T, Mashaghi A. Dry eye disease: emerging approaches to disease analysis and therapy. J Clin Med. 2019;8:1439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Polatlı Duatepe State Hospital, Department of Ophthalmology, Ankara, Turkey

    Zeynep Katipoğlu

  2. Kırşehir Ahi Evran Training and Research Hospital, Kırşehir, Turkey

    Rafiye Nur Abay

Authors
  1. Zeynep Katipoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rafiye Nur Abay
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: ZK, RNA; Methodology: ZK, RNA; Formal analysis and investigation: ZK, RNA; Writing - original draft preparation: ZK; Writing - review and editing; ZK, Supervision: ZK, RNA.

Corresponding author

Correspondence to Zeynep Katipoğlu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katipoğlu, Z., Abay, R.N. The relationship between dry eye disease and anticholinergic burden. Eye 37, 2921–2925 (2023). https://doi.org/10.1038/s41433-023-02442-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41433-023-02442-x

Search

Advanced search

Quick links